A novel cDNA, IA-2p, was isolated from a mouse neonatal brain library. The predicted protein sequence revealed an extracellular domain, a transmembrane region, and an intracellular domain. The intracellular domain is 376 amino acids long and 74% identical to the intracellular domain of IA-2, a major autoantigen in insulin-dependent diabetes mellitus (IDDM). A partial sequence of the extracellular domain of IA-2p8 indicates that it differs substantially (only 26% identical) from that of IA-2. Both molecules are expressed in islets and brain tissue. Forty-six percent (23 of 50) of the IDDM sera but none of the sera from normal controls (0 of 50) immunoprecipitated the intracellular domain of IA-2,3. Competitive inhibition experiments showed that IDDM sera have autoantibodies that recognize both common and distinct determinants on IA-2 and IA-213. Many IDDM sera are known to immunoprecipitate 37-kDa and 40-kDa tryptic fragments from islet cells, but the identity of the precursor protein(s) has remained elusive. The current study shows that treatment of recombinant IA-2p and IA-2 with trypsin yields a 37-kDa fragment and a 40-kDa fragment, respectively, and that these fragments can be immunoprecipitated with diabetic sera. Absorption of diabetic sera with unlabeled recombinant IA-2 or IA-2f8, prior to incubation with radiolabeled 37-kDa and 40-kDa tryptic fragments derived from insulinoma or glucagonoma cells, blocks the immunoprecipitation of both of these radiolabeled tryptic fragments. We conclude that IA-2,8 and IA-2 are the precursors of the 37-kDa and 40-kDa islet cell autoantigens, respectively, and that both IA-2 and IA-2p8 are major autoantigens in IDDM.
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IA-2 is a transmembrane protein with a molecular mass of 106 kDa and was recently cloned, sequenced, and expressed in a reticulocyte transcription/translation system (1, 2). By using recombinant IA-2 as a source of antigen, close to 70% of patients with insulin-dependent diabetes mellitus (IDDM) were found to have autoantibodies to this protein (M.S.L., C. Wasserfall, N.K.M., and A.L.N., unpublished results) and the presence of these autoantibodies was shown to be a good predictive marker for identifying individuals at high risk of developing IDDM (M. I. Hawa, R.E. Rowe, M.S.L., A.L.N., P. Pozzilli, M.R. Christie, and R.D.G. Leslie, unpublished results). Of particular interest was the finding that many patients who had autoantibodies to islet-cell antigens as measured by immunofluorescence (3) but who did not have antibodies to GAD65, another important autoantigen in IDDM (4) , were positive for autoantibodies to IA-2. Absorption of diabetic sera with recombinant GAD65 and/or IA-2 removed much, but not all, of the immunofluorescent reactivity of the diabetic serum
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with islet cells, suggesting that other still unidentified autoantigens were involved in the islet cell autoantibody response.
Recently, 21 members of the protein tyrosine phosphatase (PTP) family were identified from short nucleotide sequences isolated from a polymerase chain reaction (PCR)-amplified cDNA library that was constructed with cDNAs reversetranscribed from pancreatic j3 cells and a pair of degenerative primers derived from known PTP nucleotide sequences (J.L., Q.L., G. Donadel, A.L.N. and M.S.L., unpublished results). Three of these 21 PTPs were previously unknown. One of them showed considerable sequence similarity to IA-2. In this report, we describe the molecular cloning of the intracellular domain of this molecule, designated IA-2p, characterize it as an autoantigen in IDDM, and show its relationship to a 37-kDa tryptic fragment from insulinoma cells to which IDDM patients are known to have autoantibodies (5). GBq) was added to the culture for 5 h. The labeled cells were harvested and the membrane fraction was prepared as described (8).
MATERIALS AND METHODS

Cloning
Immunoprecipitation and Blocking of 37/40-kDa Tryptic Fragments from IA-2p3/IA-2 Autoantigens. Radiolabeled cell lysates (1 x 107 cpm) were precipitated with diabetic serum overnight and coprecipitated with protein A-agarose beads. After being washed three times with precipitation buffer, the beads were washed with water once and incubated with trypsin (50 or 100 ,ug/ml) on ice for 20 min. The precipitate was washed once again with water, boiled in 1 x SDS sample buffer, and separated on a 10% SDS/PAGE gel. The blocking reaction was performed by preincubation of the serum with a reticulocyte lysate containing the unlabeled intracellular domain of IA-2 or IA-213 for 2 h. Radiolabeled cell lysate was added, precipitated, and trypsinized as described above. Labeled reticulocyte lysates of full-length IA-2 and the intracellular domains of IA-2 and IA-2,B were also directly treated with trypsin (50 ,ug/ml) on ice for 20 min before loading on a 10% SDS/PAGE gel. Fig. 2A shows that a 5.5-kb mRNA band was prominent in the insulinoma cell line J3TC-1 and brain, less prominent in the glucagonoma cell line aTC-1, pancreas, and stomach, and barely detectable in colon. The other tissues tested including thymus, ovary, muscle, skin, heart, kidney, spleen, and liver were negative. For comparison, Northern blot analysis was performed on aTC-1 and ,BTC-1 cells with a 32P-labeled IA-2 sequence as the probe. Fig. 2B shows that a 3.8-kb mRNA band was very prominent in aTC-1 cells but less prominent in fTC-1 cells. A weaker signal of larger message was detected in aTC-1 cells that may be the result of alternative splicing. Because of its sequence similarity with IA-2 and strong expression in 3TC-1 cells, we refer to this new cDNA as IA-2(3.
RESULTS
Immunoprecipitation of Intracellular Domain of IA-2,8 with IDDM Serum. The intracellular domain of IA-2,B (aa 351-723) was translated into a 41-kDa product in a TNT-coupled rabbit reticulocyte system. Radiolabeled IA-2p3 then was immunoprecipitated with serum from IDDM patients and separated on a 10% SDS/PAGE gel. Fig. 3 Inset shows seven representative sera from IDDM patients that recognized the in vitro-translated product. The intensity of the bands ranged from 1 + to 4+. Fifty coded sera from diabetic patients and 50 coded sera from controls then were tested by radioimmunoprecipitation for autoantibodies to the IA-213 intracellular domain. As seen in Fig. 3 , 46% of the sera from IDDM patients, but none of the sera from controls, reacted with IA-2,3.
Identification by Competitive Immunoprecipitation of Cross-Reactive Autoantibodies to the Intracellular Domains of IA-2 and IA-213. By using the rabbit reticulocytes transcription/translation system, the intracellular domains of IA-2 (aa 604-979) and IA-2,B (aa 351-723) translated into a 42-kDa product and a 41-kDa product, respectively. As seen in Fig. 4A also with IA-2,B, precipitating a 42-kDa protein and a 41-kDa protein, respectively. The difference in the intensity of the reactivity of the rabbit hyperimmune sera with IA-2 and IA-2,B may reflect a difference in the epitopes recognized on these two molecules. Sera from diabetic patients (sera 77 and 85) recognized and precipitated radiolabeled IA-2 and IA-2f3 and both unlabeled IA-2 and IA-283 blocked this precipitation (Fig.  4B) . Some diabetic sera (e.g., serum 91a) that recognized both IA-2 and IA-2,B could be blocked by a 10-fold excess of unlabeled IA-213 (compared to radiolabeled antigen) but not by the same concentration of IA-2. Higher concentrations of unlabeled IA-2 (50-fold excess) were required for blocking the same serum (e.g., serum 91b), arguing that the autoantibodies in this serum have a higher affinity for and/or recognize predominantly the IA-283 epitopes. Still other diabetic sera (e.g., serum 79) recognized only IA-2, and the reaction could be blocked by IA-2 but not by IA-2,B. Thus, these studies show that autoantibodies to IA-2 and IA-2f3 have a high degree of cross-reactivity and that both common 2) , intracellular domain of IA-2 (lanes 3 and 4), and IA-2,B (lanes 5 and 6) were trypsinized (50 ,ug/ml) before electrophoresis on a 10% SDS/PAGE gel. subjected to trypsin treatment. As seen in Fig. 5 , the predominant tryptic fragment migrated as a 40-kDa band. In contrast, the tryptic fragment of intracellular domain of IA-2,B (41 kDa) migrated as a 37-kDa band. Both tryptic fragments could be precipitated by diabetic sera (data not shown).
Blocking of 37/40-kDa Tryptic Fragments from Islet Cells by the Intracellular Domain of IA-2p and/or IA-2. To further show that the 37-and 40-kDa tryptic fragments were derived from IA-2,B and IA-2, tryptic fragments from aTC-1 and ,BTC-1 cell lines were precipitated with diabetic sera. As seen in Fig. 6 , diabetic sera precipitated only a 40-kDa band from aTC-1 cells and a 37/40-kDa doublet from ,BTC-1 cells. These findings are consistent with the relative abundance of IA-2 mRNA in aTC-1 and IA-213 mRNA in ,BTC-1 cells (Fig. 2) . Blocking experiments (Fig. 6A) showed that both unlabeled recombinant IA-2 and IA-2,3 were capable of preventing the precipitation of radiolabeled IA-2 and IA-2f by diabetic sera from patient A. Similarly, unlabeled recombinant IA-2 completely blocked the precipitation of radiolabeled IA-2 by diabetic serum from patient B, but unlabeled recombinant IA-2f3 was somewhat less effective (e.g., xTC-1 cells) (Fig. 6B) . This may be due to the different epitopes recognized on IA-2 and IA-2f3 molecules by sera from different diabetic patients.
DISCUSSION
IA-2 is a novel receptor-type PTP isolated from a human insulinoma subtraction library (1) and now known to be a major autoantigen in IDDM. Further studies led to the identification of 21 PTPs in pancreatic islets, three of which were novel. In the present study, the entire sequence of the intracellular and transmembrane domain and a partial sequence of the extracellular domain of one of these novel PTPs, IA-2j, were determined. Our data indicate that IA-213 is closely related but different than IA-2. The intracellular domain of shows 74% identity to the intracellular domain of IA counterpart. Efforts are now underway to isolate human IA-2p by using mouse IA-2,B cDNA as the probe.
Autoantibodies to islet-cell antigens have been the subject of a number of reports (9) (10) (11) (12) (13) . In 1990, Christie et al. (8) reported that a radiolabeled lysate of insulinoma cells incubated with diabetic sera and then treated with trypsin resulted in the precipitation of 37-kDa and 40-kDa fragments. Autoantibodies to these fragments were found in a high percentage of diabetic patients and their presence in nondiabetic subjects was highly predictive of the subsequent development of IDDM (14) (15) (16) . Since autoantibodies to the 37-kDa and 40-kDa tryptic fragments showed a strong positive correlation, it was suggested that these antibodies bound to epitopes common to both fragments (5) . However, the identity of the precursor protein(s) from which these tryptic fragments were derived remained unclear. Recently, Christie and coworkers (17) reported, based on blocking experiments with the intracellular domain of IA-2, that IA-2 appears to be the precursor of the 40-kDa, but not the 37-kDa, fragment, Our data, in fact, showed that recombinant IA-2 and IA-2,B yielded tryptic fragments of 40 kDa and 37 kDa, respectively. Moreover, both unlabeled recombinant IA-2 and IA-213 blocked the binding of diabetic sera to the 40-kDa and 37-kDa tryptic fragments prepared from insulinoma cells. Therefore, we conclude that IA-2 is the precursor of the 40-kDa tryptic fragment and IA-213 is the precursor of 37-kDa tryptic fragment.
The cloning and sequencing of IA-2 and IA-2,8 and the identification of these molecules as major autoantigens are first steps in elucidating their roles in the pathogenesis of IDDM. The development of a panel of autoantibody assays using recombinant IA-2 and/or IA-2,B together with recombinant GAD65 should provide a powerful tool for screening large populations and accessing their relative predictive values in identifying individuals at high risk for IDDM.
